The Federal Trade Commission (FTC) has filed a lawsuit against Hims & Hers Health, Inc., alleging the company misled consumers by charging for prescriptions immediately after intake forms were submitted, despite promising consultations to find suitable treatments. This legal action caused a decline in the company's stock price. Following the lawsuit, Holzer & Holzer, LLC announced an investigation into whether Hims & Hers complied with federal securities laws and is encouraging affected investors to seek legal advice. This development raises concerns about the company's business practices and potential financial repercussions for shareholders.
Wall Street experienced a significant selloff with the Nasdaq 100 nearing correction territory and the Dow Jones dropping over 1,000 points, wiping out recent gains. The selloff is driven by fears of rising interest rates after three Federal Reserve ...
The U.S. Federal Trade Commission (FTC) has sued telehealth company Hims & Hers for allegedly sharing users' sensitive health data with advertisers like Meta and Snap, despite promising privacy. The FTC also accused the company of deceptive billing, ...
The Federal Trade Commission sued telehealth company Hims & Hers, accusing it of improperly sharing sensitive user health data with advertisers like Meta and Snap without consent. The FTC also alleges the company charged customers for prescriptions b...
The Federal Trade Commission, along with California and Utah, has sued telehealth company Hims & Hers for allegedly charging patients for prescription subscriptions without their consent and sharing sensitive health data with tech giants like Meta an...
Hims & Hers Health, Inc. is an innovative telehealth company that uses AI-driven processes and comprehensive patient data to create a competitive advantage difficult for others to replicate. Its vertical integration and scale further strengthen its m...
